The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Detection of circulating TTR aggregates: a potential novel biomarker for ATTR amyloidosis
Lorena Saelices Gomez, PhD, UT Southwestern Medical Center, Dallas, TX, discusses her work in which transythretin (TTR) aggregates were detected in the blood of patients with ATTR amyloidosis using a peptide probe, which could potentially serve as a novel biomarker in this disease setting. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for scientific consulting for Intellia and Attralus
Member of the advisory board of Alexion
